These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 16978039)

  • 1. Extended-release intramuscular naltrexone: a viewpoint by Falk Kiefer.
    Kiefer F
    Drugs; 2006; 66(13):1752-3. PubMed ID: 16978039
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.
    Siegel S
    Drugs; 2006; 66(13):1752. PubMed ID: 16978040
    [No Abstract]   [Full Text] [Related]  

  • 3. Extended-release intramuscular naltrexone: a viewpoint by Henry R Kranzler.
    Kranzler HR
    Drugs; 2006; 66(13):1753-4. PubMed ID: 16978038
    [No Abstract]   [Full Text] [Related]  

  • 4. Extended-release intramuscular naltrexone.
    Swainston Harrison T; Plosker GL; Keam SJ
    Drugs; 2006; 66(13):1741-51. PubMed ID: 16978037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vivitrex (Alkermes/Cephalon).
    Heading CE
    Curr Opin Investig Drugs; 2006 Jan; 7(1):81-8. PubMed ID: 16425675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence.
    O'Brien CP
    Curr Psychiatry Rep; 2005 Oct; 7(5):327-8. PubMed ID: 16216149
    [No Abstract]   [Full Text] [Related]  

  • 7. A synopsis of the pharmacological rationale, properties and therapeutic effects of depot preparations of naltrexone for treating alcohol dependence.
    Johnson BA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1065-73. PubMed ID: 16722816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [An interim analysis of the results of treatment program implementation with the use of injectable extended-release naltrexone for opioid addicted patients].
    Agibalova TV; Nedobylskiy OV; Poplevchenkov KN; Sirotko II; Shcherban AV; Tsarev SA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(6):32-34. PubMed ID: 28745668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Naltrexone (vivitrol)--a once-monthly injection for alcoholism.
    Med Lett Drugs Ther; 2006 Jul; 48(1240):63-4. PubMed ID: 16874283
    [No Abstract]   [Full Text] [Related]  

  • 10. [Alcohol dependence and mental adaptation disorders (the use of injectable extended-release naltrexone)].
    Agibalova TV; Rychkova OV; Kuznetsov AG; Gurevich GL; Val'chuk DS; Petrov AD
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(6 Pt 2):63-8. PubMed ID: 23887471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preliminary evaluation of extended-release naltrexone in Michigan and Missouri drug courts.
    Finigan MW; Perkins T; Zold-Kilbourn P; Parks J; Stringer M
    J Subst Abuse Treat; 2011 Oct; 41(3):288-93. PubMed ID: 21696912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should Long-Acting Depot Intramuscular Naltrexone Be Prescribed Every 3 Weeks for Alcohol Use Disorder?
    Luvisi J; Ahonen K; Sethi R
    Prim Care Companion CNS Disord; 2019 May; 21(3):. PubMed ID: 31106994
    [No Abstract]   [Full Text] [Related]  

  • 13. Implementation of Oral and Extended-Release Naltrexone for the Treatment of Emergency Department Patients With Moderate to Severe Alcohol Use Disorder: Feasibility and Initial Outcomes.
    Anderson ES; Chamberlin M; Zuluaga M; Ullal M; Hawk K; McCormack R; D'Onofrio G; Herring AA
    Ann Emerg Med; 2021 Dec; 78(6):752-758. PubMed ID: 34353648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Retention in naltrexone implant treatment for opioid dependence.
    Kunøe N; Lobmaier P; Vederhus JK; Hjerkinn B; Hegstad S; Gossop M; Kristensen O; Waal H
    Drug Alcohol Depend; 2010 Sep; 111(1-2):166-9. PubMed ID: 20570059
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-acting injectable naltrexone for the treatment of alcohol dependence.
    Mannelli P; Peindl K; Masand PS; Patkar AA
    Expert Rev Neurother; 2007 Oct; 7(10):1265-77. PubMed ID: 17939765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in opioid antagonist treatment for opioid addiction.
    Ling W; Mooney L; Wu LT
    Psychiatr Clin North Am; 2012 Jun; 35(2):297-308. PubMed ID: 22640757
    [No Abstract]   [Full Text] [Related]  

  • 17. Extended-release intramuscular naltrexone in alcohol dependence in adults: profile report.
    Swainston Harrison T; Plosker GL; Keam SJ
    CNS Drugs; 2007; 21(1):83-7. PubMed ID: 17190531
    [No Abstract]   [Full Text] [Related]  

  • 18. Holidays, triggers, and willpower--is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients".
    Rosenbloom DL
    J Subst Abuse Treat; 2009 Jan; 36(1):7. PubMed ID: 19038694
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility.
    Fishman MJ; Winstanley EL; Curran E; Garrett S; Subramaniam G
    Addiction; 2010 Sep; 105(9):1669-76. PubMed ID: 20626723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic basis for predicting response to naltrexone in the treatment of alcohol dependence.
    Anton RF
    Pharmacogenomics; 2008 Jun; 9(6):655-8. PubMed ID: 18518841
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.